
COVIDã¯ã¯ãã³ã§å¿èã«ç°åžžããããã人ãããããšãè§£ååŠçã«å€æ
å èšäºã¯ãã¡ã/Original article here
COVID-19ã¯ã¯ãã³ã«é¢é£ããé節ãªå¯äœçšã¯ãæ»ã«è³ãå¯èœæ§ãããããšããæ°ããç ç©¶ã§æããã«ãªã£ãã
ã¯ã¯ãã³æ¥çš®åŸã®å¿ççïŒå¿èã®ççã®äžçš®ïŒã¯ãCOVID-19ã¯ã¯ãã³ãæ¥çš®ããŠãã20æ¥ä»¥å ã«èªå® ã§ãäºæãããæ»äº¡ãã人ã ã®ãµãã»ããã§ç¢ºèªãããŸããã
ç ç©¶è ãã¡ã¯ããã®äººãã¡ã«å¯ŸããŠè¡ãããæ€æ»ãåæããçµç¹ãµã³ãã«ãç ç©¶ãããªã©ããããªã調æ»ãè¡ããŸããã
ç ç©¶è ãã¡ã¯35人ã®ã°ã«ãŒãããã¹ã¿ãŒãããããä»ã®æ»å ãç¹å®ãããããã10人ããããªãåæããé€å€ãããæ®ãã®25人ã®ãã¡ã5人ã«å¿ççã®èšŒæ ã確èªãããŸããã
ãã®5人ã¯å šå¡ãæ»äº¡åŸ7æ¥ä»¥å ã«ModernaãPfizerã®ã¯ã¯ãã³ãåããŠãããå¹³å2.5æ¥ã§ãã£ãã
幎霢ã®äžå€®å€ã¯58æ³ã§ãã£ããã¯ã¯ãã³æ¥çš®åã«COVID-19ã«ææããŠãã人ã¯ãããã錻è ã¹ã¯ããé°æ§ã§ãã£ãã
æ€æ»ã®çµæãä»ã®æ»å ã®èšŒæ ããªãããšãã¯ã¯ãã³æ¥çš®ãæ»ã®çŽåã«è¡ãããããšãªã©ãçžãŸã£ãŠãç ç©¶è ã¯3äŸã«ã€ããŠãã¯ã¯ãã³æ¥çš®ãå¿ççã®ãåå ãšèããããããã®ã§ãå¿çŸæ£ããçªç¶æ»ã®åå ã§ããããšçºè¡šããŸããã
ä»ã®1äŸã§ã¯ãå¿ççãæ»å ãšèããããããç ç©¶è ã¯ãã«ãã¹ãŠã€ã«ã¹ãæ€åºããå¿èã®ççãçºçããããšã®ä»£æ¿èª¬æãšããã
æ®ãã®1äŸã¯ãå¿ççã®ä»£æ¿èª¬æãå«ãŸããŠããŸããã§ããããç ç©¶è ã¯ãççã®åœ±é¿ã ã颿£çã§ãäž»ã«å¿èèèªã«èгå¯ãããããšè¿°ã¹ãŠããŸãã
圌ãã¯ããã®2ã€ã®çäŸãã¯ã¯ãã³æ¥çš®ãåå ã§ããå¯èœæ§ããããšåé¡ããŠããŸãã
ãäžè¬çã«ãå¿ççãšæSARS-CoV-2ã¯ã¯ãã³æ¥çš®ã®å æé¢ä¿ã¯ãããã€ãã®èæ ®äºé ã«ãã£ãŠæ¯æãããããšç ç©¶è ã¯è¿°ã¹ãŠããããã¯ã¯ãã³æ¥çš®ãšã®å¯æ¥ãªæéçé¢ä¿ãããä»ã®éèŠãªæ¢åŸå¿èçŸæ£ããªããããå¿ççã®åå ãšãªãæææ§ç©è³ªãé°æ§ããªã©ãæããããã
å¶éäºé ãšããŠã¯ãã³ããŒãèŠæš¡ãå°ããããšãæããããŸãã
ãã®ç ç©¶ã¯ã11æ27æ¥ã«Clinical Research in Cardiologyèªã«æ²èŒããããç ç©¶è ãã¯å šå¡ãã€ãã«ãã«ã¯å€§åŠç é¢ã«å€åããŠããã圌ãã¯ããã€ãåœå±ããè³éæäŸãåããŠããã
ã¢ãã瀟ãšãã¡ã€ã¶ãŒç€Ÿã¯ãã³ã¡ã³ãã®èŠè«ã«å¿ããªãã£ãã
ããŒãã¢ã€ã©ã³ãã«æ¬æ ã眮ãå¿èå°éå®¶ã¢ã³ããªã¥ãŒã»ãã¹ãã å士ã¯ãšããã¯ã¿ã€ã ãºçŽã«ãã¯ã¯ãã³æ¥çš®ä»¥å€ã®å¯èœæ§ãæé€ããããšã¯ããã®ã±ãŒã¹ããæ°·å±±ã®äžè§ãã§ããããšã瀺åããŠããã
ãäžèŠå¥åº·ããã«èŠãã人ãå¯ãŠããéã«çªç¶æ»ãã å Žåãåºæ¬çã«ããã®ãããªã±ãŒã¹ã¯éåžžè§£åãããããããŠãæããã«æãäžè¬çãªæèŠã¯ãããçš®ã®ã¢ãããŒã æ§å ç¶åèæ§å¿èç ã§ããããããããããã®çäŸã§ã¯ãåºæ¬çã«ãããé€å€ããŠããŸãããããŠãæã劥åœãªè¿å ã¯ã¯ã¯ãã³æ¥çš®ã§ãããšçµè«ã¥ããã®ã§ãããšåœŒã¯èšãã
ããããŠããã®çŸè±¡ã¯ããããŸã§çãããŠãããããåºãç¯å²ã«åã¶å¯èœæ§ãããããšã瀺åããŠããã®ã§ããã
å¿çç
å¿ççã¯ãèžã®çã¿ãšããŠçŸããé節ãªå¿èç ã§ãããéåžžãæ£è ã¯ç é¢ã§ã®æ²»çãåããããšã«ãªããŸãã
éåžžãå»åž«ã¯äžå®æéããã¹ãŠã®ããããã¯ã»ãšãã©ã®èº«äœæŽ»åãæ§ããããå©èšããŸãã
åå ãšããŠã¯ã现èããŠã€ã«ã¹ãçºç±ãªã©ãæããããŸãã
æ¥æ§å¿ççã¯ãæåã®2ã4é±éã§çŽåæ°ã®çäŸãæ²»çãããã4åã®1ã¯é·æçãªåé¡ãæ±ããæ®ãã®å€ãã¯æ»äº¡ãŸãã¯å¿èç§»æ€ã«è³ãããšãç ç©¶è ã«ãã£ãŠæããã«ãããŠããã
COVID-19ã¯ã¯ãã³æ¥çš®è ã®å¿çççºççã¯äºæ³ä»¥äžã«é«ãããšããç±³åœãã€ã¹ã©ãšã«ããã®ä»ã®åœã ã®ç ç©¶è ã«ããæããã«ãããŸããã
æãé«ãçºççã¯ãè¥è ãç¹ã«è¥ãç·æ§ã§æ€åºãããŠããã
å žåçãªå¿ççã®çºççã¯ã7æ¥ä»¥å ã«100äžäººããã0.2ã2.2人ã§ãããšæšå®ãããŠããŸãã
ã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ãžã®å ±åã«ãããšã5æ³ãã49æ³ã®ç·æ§ã12æ³ãã29æ³ã®å¥³æ§ã§é«ãçºççã確èªãããŠããŸãã
æãé«ãçºççã¯ã100äžåç®ã®æäžããã75.9人ã§ãããåã·ã¹ãã ãžã®å ±åã¯å æé¢ä¿ã蚌æãããã®ã§ã¯ãªãããç ç©¶ã«ããã°ãåã·ã¹ãã ã¯æ·±å»ãªéå°å ±åã«æ©ãŸãããŠããããã®å²åã¯ããã«é«ãããšã瀺ãããŠããã
ç±³çŸç 察çã»ã³ã¿ãŒïŒCDCïŒã¯ãçåŸ6ã«æä»¥äžã®ã»ãŒãã¹ãŠã®äººã«ã¯ã¯ãã³æ¥çš®ãæšå¥šãç¶ããŠãããã¯ã¯ãã³ã®å©ç¹ã¯ãªã¹ã¯ãäžåããšäž»åŒµããŠããã
ããããå°éå®¶ã®äžã«ã¯ãå¿ççã®ãããªå¯äœçšãããããã幎霢局ã«ãã£ãŠã¯ãªã¹ã¯ãé«ããªããšèšã人ãããã
æ¿åºé¢ä¿è ã¯ãå¿ççã®ã»ãšãã©ã¯æ°é±éã§æ²»ããšç¹°ãè¿ãèšã£ãŠããããCDCã®ç ç©¶è ã¯9æã«ãã¯ã¯ãã³æ¥çš®åŸã®å¿ççãçµéšããè¥è ã®å€ãããæ°ãµæåŸã«ãŸã MRIã®çµæã«ç°åžžãããããšãçºèŠããŠããã
ã¯ã¯ãã³æ¥çš®åŸã«æ»äº¡ãã人ã®åæ€çµæãå皮調æ»ã®å ¬éãæãã§ããç±³åœå±ã«ãããšãé«éœ¢è ã§ã®çºççã¯ããªãäœããšã®ããšã ã
ãããªãå·ä¿å¥å±ã«å©èšããç«åŠè ã®ãã¬ã€ã·ãŒã»ããšã°å士ã¯ãã€ãã¿ãŒã§ããæ°ããç ç©¶ã¯ãããããã®ç ç©¶ã§é床ã®ããª[å¿çç]ã®çäŸãèŠéããŠããããšã瀺åããŠããããšè¿°ã¹ãã
å æé¢ä¿
ããã€ãã®ã¯ã¯ãã³ã¯å¿ççãšãã®é¢é£çŸæ£ã§ããå¿èçãšé¢é£ããããšãããŠããŸãããããã¯ModernaãšPfizerã«ãã£ãŠäœãããç±³åœãšãã€ãã§æãåºãæäžãããŠãã2ã€ã§ãã
ã©ã¡ãã®ã¯ã¯ãã³ãã¡ãã»ã³ãžã£ãŒRNAïŒmRNAïŒæè¡ãå©çšããŠããŸãã
å æé¢ä¿ãšã¯ãã¯ã¯ãã³ãããç¶æ ãåŒãèµ·ããããšãæå³ããã
CDCã®ãããç ç©¶è ã¯ãçŸåšã®ãšãããmRNA泚å°ãšå¿èã®ççãšã®éã«å æé¢ä¿ãããããšã瀺ã蚌æ ããããšè¿°ã¹ãŠãããä»ã®ç ç©¶è ããã®ãããªçµè«ã«éããŠããã
ç±³åœé£åå»è¬åå±ïŒFDAïŒã¯ãæœåšçãªã¯ã¯ãã³æ¥çš®è ã«ãåžè²©åŸã®ããŒã¿ã¯ãç¹ã«2åç®ã®æ¥çš®åŸ7æ¥ä»¥å ã«å¿ççãå¿èçã®ãªã¹ã¯ãé«ãŸãããšã瀺ããŠããããšèŠåããŠããã
ãã¹ãã æ°ã¯ã圌ãã¬ãã¥ãŒãã蚌æ ã¯å æé¢ä¿ã瀺ããŠãããšè¿°ã¹ãã
ãå»åŠã®äžçã§ç¢ºèªãããŠããã»ãšãã©ã®é¢é£æ§ãšåãããã確ããªããšã§ãããšåœŒã¯è¿°ã¹ãã
ããã€ãã®ç ç©¶ã§ã¯ãCOVID-19ãå¿ççãå¿èçã®å¥ã®åå ã§ãããšãããŠããŸãããä»ã®ç ç©¶ã§ã¯é¢é£æ§ããªãå¯èœæ§ãææãããŠããŸãã
ãã®ä»ã®è§£åæèŠ
ãã€ãã®ç 究以åã«ãäžçäžã®ä»ã®ç ç©¶è ããã¯ã¯ãã³æ¥çš®åŸã«æ¥æ»ãã人ã®è§£åããåŸãããç¥èŠãå ±åããŠããŸãã
2021幎ãç±³åœã®ç ç©¶è ã¯ãCOVID-19ã¯ã¯ãã³æ¥çš®åŸ2é±é以å ã«2äººã®æäººãå¿ççãçºçããã¯ã¯ãã³æ¥çš®ä»¥å€ã®åå ãèŠã€ããããšãã§ããªãã£ããšå ±åããŸããã
2021幎ãéåœã®ç ç©¶è ã¯ããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ãæ¥çš®ãã5æ¥åŸã«æ»äº¡ãã22æ³ã®ç·æ§ã®æ»äº¡äºäŸã調æ»ããçµæãäž»ãªåå ã¯ã¯ã¯ãã³ãšã®å æé¢ä¿ããããå¿ççãã§ãããšå€æãããšå ±åããŸããã
1æããã¥ãŒãžãŒã©ã³ãã®ç ç©¶è ã¯ã57æ³ã®å¥³æ§ãæ»ã«è³ããããçªç¶ã®å¿ççã¯ããããããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ã«èµ·å ãããšå ±åãããä»ã®åå ã¯åççãªç¢ºä¿¡ãæã£ãŠå²ãåŒãããŠãã ããšæžããŸããã
2æã«ã¯ãã¢ã¡ãªã«ã®ããã€ãã®å·ã®ç ç©¶è ãããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ãæ¥çš®ããçŽåŸã«æ»äº¡ãã2人ã®10代ã®å°å¹Žã«å¿èã®ççãèµ·ããããã®ççãäž»ãªæ»å ã§ãã£ããšå ±åããŸããã
5æã«ã¯ãCDCã®ç ç©¶è ããã¯ã¯ãã³æ¥çš®åŸã«å¿èã®ççãèµ·ãããŠæ»äº¡ããå°å¹Žããããå¿ççãæ»å ãšæšå®ããããšå ±åããŸããã
9æã«ã¯ããã€ãã®ç ç©¶è ãããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ãæ¥çš®ãã4ãµæåŸã«æ»äº¡ãã55æ³ã®ç·æ§ãå¿ççã§æ»äº¡ãããšå ±åããããããã®ç¥èŠã¯ãå¿ççãããã³ã¹ãã€ã¯èªçºéºäŒåããŒã¹ã®ã¯ã¯ãã³æ³šå°åŸã®è¡æ 塿 äºè±¡ããã³ãŒãåãããè¬å€ã«å¯Ÿããæå®³ãªå ç«åå¿ãšå æé¢ä¿ãããããšã瀺ããŠããŸãããšè¿°ã¹ãŠããŸãã
ãããŠãã€ãæè¿ãæ¥æ¬ã®ç ç©¶è ããã¯ã¯ãã³æ¥çš®åŸã®å ¥é¢ãã28æ¥åŸã«æ»äº¡ãã27æ³ã®ç·æ§ã®çµæãå ±åããŸããã